You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Tests in development for the Alere q include HIV, tuberculosis, and Ebola assays, and it will initially be targeted to low-resource settings in the developing world.
The firm has also created a qPCR-based Staphylococcus aureus resistance gene assay with a run time of three minutes.
Biocartis will initially test the device against synthetic virus samples and subsequently run trials in West Africa.
Other collaborators include the Institute Pasteur, the Organization of International Visitors of the USA, and Thermo Fisher Scientific.
Recurring revenues drove growth during the quarter, while instrument revenues also improved year over year.
The test would allow healthcare workers to differentiate Ebola from other diseases that mimic the virus, a trait which presented problems during the recent crisis in West Africa.
The team tracked down several hundred SNPs in the Ebola genome, including mutations that could alter the effectiveness of treatments targeting certain virus sequences.
Trends included expanding test menus and a possible tipping point for point-of-care.
The test, which is being developed with a National Science Foundation grant, is based on a novel PCR technology that doesn't require traditional instrumentation.
The real-time RT-PCR LightMix Ebola Zaire test runs on the Roche Light Cycler 480 or Cobas Z 480 instruments.
Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.
US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.
The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.
In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.